Showing posts with label RDT(Tuberculosis). Show all posts
Showing posts with label RDT(Tuberculosis). Show all posts

Thursday, 21 July 2011

TUBERCULOSIS: .World Health Organization calls for TB blood test ban

Matt McGrath : 21 July 2011 BBC World Service Science reporter
TB bacteria TB can lie dormant for years

Blood tests designed to detect active TB are inaccurate and should be banned, the World Health Organization has said.
More than two million such tests are carried out annually, but the WHO says they are unethical and lead to misdiagnosis and the mistreatment of patients.
The organisation's review of these tuberculosis test kits says they give wrong results in around 50% of cases.
The kits are mainly sold in the developing world.
However, most of the 18 kits on the market are produced in Europe and North America.
According to Dr Mario Raviglone, the director of the WHO Stop TB Department, the tests must be banned.
He said: "A blood test for diagnosing active TB disease is bad practice. Tests are inconsistent, imprecise and put patients' lives in danger."
The tests work by detecting antibodies or antigens in the blood that are produced in response to the bacterium.
But some of these commercial tests have what's called "low sensitivity" which leads to large numbers of patients being told they do not have TB when they do.

'Unethical'
Dr Karen Weyer, who is also from the WHO Stop TB department, added: "The evidence we reviewed over the past couple of months shows that one in two patients will be wrongly diagnosed, either [as] false negative or false positive.
"If it's a false negative patients get the all clear when they in fact have TB, the disease continues to spread, and the patients may die. "If, on the other hand, it's false positive, patients are put on treatments unnecessarily while the true cause of their disease remains undiagnosed." "We would describe this as unethical - and we are making a very strong urge to governments to consider that TB is a threat and the use of these ineffective tests is also a threat."

The WHO says that the tests which are manufactured in Europe and North America are prevented from going on sale where they are made due to regulations that call for extensive evidence of accuracy.
But this is not the case in the developing world - including in India and China.
Dr Weyer added: "One of the major problems is that these developing countries often have little or very weak regulatory mechanisms to make sure that tests are registered before they are used at country level.
"Another problem is that these tests are often used in the private sector, which is a difficult sector to regulate and as a result there is a wide misuse, I would say, of these inaccurate tests in the private sector in at least 17 countries that we are aware of."
She said there was a need for a TB test that could be used "at the bedside". But she added: "We don't have a blood test for TB that can be used at the point of care level."
The WHO says this call for a ban is a highly unusual move - It's the first time the organisation has issued an explicitly negative policy recommendation against a practice that is widely used in tuberculosis care.
TB kills 1.7m people every year, and is the biggest cause of death of people living with HIV.

http://www.bbc.co.uk/news/health-14234575

Tuesday, 5 April 2011

TUBERCULOSIS: Chembio Awarded Phase II NIH Grant for Rapid TB Test

 March 29, 2011
Chembio Diagnostics, Inc. has been awarded a three-year $ 2.9 million Small Business Innovative Research (SBIR) Phase II grant from the United States National Institutes of Health (NIH) to continue development of a simple, rapid, accurate, and cost-effective serological test for active tuberculosis that can be utilized in resource-limited settings. Chembio developed a prototype of this test in the Phase I work in collaboration with the Infectious Disease Research Institute (“IDRI”); this collaboration will continue in this second phase of the research and development grant as well. The grant is effective March 1, 2011.
Tuberculosis is a chronic infectious disease, with an estimated 2 billion people currently infected worldwide and several million new cases each year. Current methods of diagnosis are slow, unreliable, and/or impractical in the field settings where the disease burden is the greatest. New diagnostics are urgently needed to address this global health problem by improving control programs.
The prototype test developed during the Phase I work uses the innovative Dual Path Platform (DPP®) technology developed and patented by Chembio, together with selected antigens from a large panel of novel recombinant antigens identified at IDRI, a Seattle-based biotechnology research organization dedicated to technologies that address diseases in the developing world.
Chembio is budgeted to receive approximately 63.5% of the awarded amount, or approximately $ 1,842,700, if award funding continues over the full three years as is expected; IDRI would receive the balance as a subcontractor to Chembio. The grant award budget is approximately equal in each grant year, or approximately $ 967,000 per year. As in all such grants, award funding in the second and third years is subject to satisfactory progress and availability of funds.
The Phase I studies demonstrated the feasibility of developing a rapid and accurate test for tuberculosis with required diagnostic performance characteristics (sensitivity > 80%, specificity > 95%). Scientists at Chembio and IDRI have identified novel serodiagnostic targets involved in the antibody response in patients with pulmonary tuberculosis and designed a set of polyepitope fusion proteins. Integrating these high-performing antigens in the Chembio proprietary DPP® technology resulted in developing a test prototype showing sensitivity of 81% and specificity of 95% in pilot evaluations of patients with active tuberculosis in endemic regions. In Phase II, the proposed rapid (15 minutes) point-of-care DPP® test for tuberculosis will be fully developed, optimized, and evaluated in multi-center clinical trials in several countries, followed by validation of production protocols, preparation for regulatory approval and commercialization.
Lawrence A. Siebert, Chembio’s President, commented, “We look forward to completing the Phase II work so that we can provide a practical tool in the diagnosis of tuberculosis. We appreciate the outstanding work that Dr. Konstantin Lyashchenko, the Chembio TB project team and our collaborators at IDRI, have all done to receive this Phase II grant and to address a large global health need.”
Dr. Steven G. Reed, IDRI’s Founder and Head of Research and Development, indicated, “We at IDRI see this Phase II funding as validation that our proprietary reagents, combined with Chembio’s DPP® technology, can contribute to more effective management of tuberculosis — and a reduction in the burden of this dangerous disease. IDRI’s collaboration with Chembio is a nice example of how public private partnerships translate good science into field-appropriate solution.”
http://www.technologybo.com/chembio-awarded-phase-ii-nih-grant-for-rapid-tb-test-2656.html

Monday, 28 March 2011

TUBERCULOSIS: WHO considers strategy to stop tuberculosis feeble

3/24/11
Luanda – The regional director of the World Health Organization (WHO) for Africa, Luís Gomes Sambo, affirmed that despite the fact that member states have adopted almost universally the strategy to stop tuberculosis, the implementation is feeble.
A message in the ambit of the World Tuberculosis Day (March 24) stated that 49 percent of the cases are annually detected, having 12 countries of the region, in 2008, achieved the internationally required goals recommended of a detection of at least 70 percent of new cases.
Gomes Sambo refers that WHO report on tuberculosis control indicates that in 2010 the African region (which represents only 12 percent of the world population) registered 23 percent of the total cases recorded worldwide.
WHO representative alerted that the cases connected to the increase of new challenges, such as co-infections TB/HIV and TB multi-resistance to medicine, complicates the control of the disease in the region, since about 35% of people with tuberculosis are HIV-positive.
Gomes Sambo said that there is the need for innovating actions to deal with the continuous challenges.
WHO will support countries to adopt new rapid test, which combines diagnosis in a unique test.
Gomes Sambo appealed to the national authorities to reinforce partnerships to stop tuberculosis in order to mobilize additional resources to control the disease, from government and private sectors.
http://www.portalangop.co.ao/motix/en_us/noticias/saude/2011/2/12/WHO-considers-strategy-stop-tuberculosis-feeble,83227e18-797e-4877-b766-45a071a4922b.html

TUBERCULOSIS: need to solve problems around the pricing and supply of DR-TB medicines

Aarti Dhar As a new rapid diagnostic test, endorsed by the World Health Organisation (WHO), will finally help detect more people with drug-resistant tuberculosis (DR-TB), there was need to solve problems around the pricing and supply of DR-TB medicines, according to a report by international medical humanitarian organisation Médecins Sans Frontières (MSF).

The DR-TB is on the rise, but less than 7 per cent of 4,40,000 new cases each year receive treatment. It kills 150,000 people in the world annually, according to the WHO. India is one of the countries with the highest burden of DR-TB cases in the world, with more than 99,000 new cases each year.
The MSF report, released to mark World TB Day, shows that DR-TB drugs are riddled with persistent supply and price problems that must be urgently addressed.
The report examines medicines used to treat DR-TB according to the number of suppliers, quality assurance and price, based on information obtained from the Global Drug Facility and drug manufacturers.
The report highlights that four of the recommended DR-TB medicines are available from only one quality-assured generic source.
Relying on a sole supplier whose production could be disrupted or stopped at any time always carries a risk of dangerous treatment interruption for patients. For example, supplies of injectable drug kanamycin were disrupted in 2010, leading to a temporary global stock out.
“In India and several other countries, resistance to TB drugs is a serious public health issue, which cannot be allowed to get worse,” said Blessina Kumar of Stop TB Partnership.
“Patients have been stuck in a vicious circle – not enough people are diagnosed, and drug supply problems along with high prices stand in the way of putting more people on treatment.”
Additionally, the MSF report found that several DR-TB medicines are very expensive, with prices for two drugs having increased by more than 600 per cent and one drug by more than 800 per cent over the last decade.
A 24-month DR-TB treatment regimen can cost as much as $9,000 for one patient — 470 times more than the $19 per patient it costs to cure standard, drug-sensitive TB.
“Now that we have a new test that can detect DR-TB in less than two hours instead of three months, we're going to see many more people who will need reliable drug supplies to get treated,” said Joanna Ladomirska, Medical Coordinator for MSF in India.
“We need to see some immediate action to improve access to DR-TB drugs so that more people are started on treatment and transmission of this disease is reduced. This is particularly important in India, given the high burden of DR-TB here,” said Ladomirska.
The low demand for DR-TB drugs had made the market unattractive for producers, which was reinforcing the supply and price problems.
One way to kick start increased production of some of these drugs is for donors to guarantee purchase volumes for several years to producers upfront.
Other mechanisms such as better forecasting of the mid-to long-term needs for DR-TB drugs are also needed to help attract more producers to the market, to improve supply security and increase competition that helps brings prices down.
“With faster diagnosis and better treatment models of the DR-TB, we need to fix the supply and price issues with DR-TB drugs. We also need to see newer drugs developed,” said Ladomirska.
http://www.thehindu.com/health/article1564679.ece